APA ציטוט

Procaccia, V., Nakayama, H., Shimizu, A., & Klagsbrun, M. (2014). Gleevec/imatinib, an ABL2 kinase inhibitor, protects tumor and endothelial cells from semaphorin-induced cytoskeleton collapse and loss of cell motility.

Citação norma Chicago

Procaccia, Vera, Hironao Nakayama, Akio Shimizu, and Michael Klagsbrun. Gleevec/imatinib, an ABL2 Kinase Inhibitor, Protects Tumor and Endothelial Cells From Semaphorin-induced Cytoskeleton Collapse and Loss of Cell Motility. 2014.

ציטוט MLA

Procaccia, Vera, Hironao Nakayama, Akio Shimizu, and Michael Klagsbrun. Gleevec/imatinib, an ABL2 Kinase Inhibitor, Protects Tumor and Endothelial Cells From Semaphorin-induced Cytoskeleton Collapse and Loss of Cell Motility. 2014.